

Câncer Gástrico e Junção Gastroesofágica

Quimioterapia concomitante a radioterapia

(Esquema de MacDonald)

5-Fluorouracil: 425 mg/m² IV D1 a D5

Leucovorin: 20 mg/m² IV D1 a D5

Radioterapia iniciando no D28 do primeiro ciclo associada a 2 ciclos de quimioterapia conforme abaixo:

5-Fluorouracil: 400 mg/m² IV D1-4 e D23-25 da radioterapia

Leucovorin: 20 mg/m² IV D1-4 e D23-25 da radioterapia

Após término da radioterapia repetir mais dois ciclos de

5-Fluorouracil: 425 mg/m² IV D1 a D5

Leucovorin: 20 mg/m² IV D1 a D5

Ref. (1)

DCF

Docetaxel: 75 mg/m² IV D1

Cisplatina: 75 mg/m² IV em 3 horas D1

5-Fluorouracil: 750 mg/m²/dia IV infusão contínua D1 a D5

a cada 21 dias

Ref. (2)

CF

Cisplatina: 100 mg/m² IV em 3 horas D1

5-Fluorouracil: 1.000 mg/m²/dia IV por infusão contínua D1 a D5

a cada 28 dias

Ref. (2)

ECF

Epirubicina: 50 mg/m² IV D1

Cisplatina: 60 mg/m² IV D1

5-Fluorouracil: 200 mg/m²/dia IV infusão contínua por 21 dias

a cada 21 dias

Ref. (4)

ELF

Etoposide: 120 mg/m² IV D1 a 3
Leucovorin: 300 mg/m² IV D1 a 3
5-Fluorouracil: 500 mg/m² IV D1 a 3
a cada 28 dias

Ref. (5)

IP

Irinotecano: 70 mg/m² IV D1 e 15
Cisplatina: 80 mg/m² IV D1
a cada 28 dias

Ref. (6)

FAM

5-Fluorouracil: 600 mg/m² IV D1, 8, 29 e 36
Adriamicina: 30 mg/m² IV D1 e 29
Mitomicina-C: 10 mg/m² IV D1
a cada 8 semanas

Ref. (7)

FAMTX

5-Fluorouracil: 1.500 mg/m² IV D1, iniciando 1 hora após o
Methotrexate
Leucovorin: 15 mg/m² VO a cada 6 horas por 12 doses,
iniciando 24 horas após início do Methotrexate
Adriamicina: 30 mg/m² IV D15
Methotrexate: 1.500 mg/m² IV D1
a cada 28 dias

Ref. (8)

FAP

5-Fluorouracil: 300 mg/m² IV D1 a 5
Adriamicina: 40 mg/m² IV D1
Cisplatina: 60 mg/m² IV D1
a cada 5 semanas

Ref. (9)

Docetaxel + Cisplatina

Docetaxel: 85 mg/m² IV D1
Cisplatina: 75 mg/m² IV D1
a cada 21 dias

Ref. (10)

5-Fluorouracil

5-Fluorouracil: 500 mg/m² IV D1 a 5

a cada 28 dias

Ref. (11)

Docetaxel

Docetaxel: 100 mg/m² IV D1

a cada 21 dias

Ref. (12)

OU

Docetaxel: 35 mg/m² IV semanalmente por 6 semanas

a cada 8 semanas

Ref. (12)

Capecitabina

Capecitabina: 2000mg/m²/dia VO D1 a D14, ciclos a cada 21 dias.

Ref.(13)

Cisplatina + Irinotecano

Cisplatina: 30 mg/m² IV

Irinotecano: 60 mg/m² IV

Semanal x 3 semanas a cada 4 semanas

Ref. (14)

FOLFOXIRI

Oxaliplatina: 85mg/m² IV em 2 horas D1

Irinotecano: 165mg/m² IV em 90 min D1

Leucovorin: 200mg/m² IV em 2 horas D1

5-Fluorouracil 3200mg/m² IV em 48 horas, infusão contínua

a cada 15 dias

Ref. (15)

EOX

Epirrubicina: 50mg/m² IV D1 a cada 3 semanas

Oxaliplatina: 130mg/m² IV D1 a cada 3 semanas

Capecitabina: 625mg/m² VO, BID, durante todo o tratamento por 8 ciclos

Ref. (16)

ECX

Epirrubicina: 50mg/m² IV D1

Cisplatina: 75mg/m² IV D1

Capecitabina: 1000mg/m² VO, BID D1 a D14

Ref. (17)

EXE

Oxaliplatina: 130mg/m² IV D1 a cada 3 semanas

Capecitabina: 1000mg/m² VO, BID, continuamente

Epirrubicina: 50mg/m² IV D1 a cada 3 semanas Ref. (18)

PELF

Cisplatina: 40mg/m² IV D1 e D5

Epirrubicina: 30mg/m² IV D1 e D5

Leucovorin: 100mg/m² IV D1 a D4

Fluorouracil: 300mg/m² IV D1 a D4

a cada 21 dias, total de 4 ciclos Ref. (19)

DF

Docetaxel: 75mg/m² IV D1

5-Fluorouracil: 200mg/m² IV D1 a D21

a cada 3 semanas Ref. (20)

ECR

Epirrubicina: 60 mg/m² IV D1

Cisplatina: 60 mg/m² IV D1

Raltitrexede: 1mg/m² IV D1 e D8

a cada 3 semanas Ref. (21)

Estudo ToGA

Trastuzumabe: 8 mg/Kg dose inicial IV Dia 1 seguido por 6 mg/kg a cada 21 dias, até a progressão ou toxicidade intolerável, associado a:

Cisplatina: 80 mg/m² Dia 1 a cada 21 dias +

5-Fluorouracil: 800 mg/m² Dias 1 a 5 em infusão contínua a cada 21 dias

OU

Capecitabina: 1g/ m² / VO 2 x ao dia Dias 1 a 14 a cada 21 dias por 6 ciclos. Ref. (22)

1. MacDonald JS, *et al.* Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001; 345: 725–730.
2. Ajani JA, *et al.* Docetaxel (D), cisplatin, 5-fluorouracil compare

- to cisplatin (C) e5-fluorouracil (F) porchemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomized phase III trial (V3325). *Proc Am Soc Clin Oncol* 2003;22:249 (abstract 999).
4. Findlay M, *et al.* A phase II study in advanced gastro-esophageal cancer using epirubicin ecisplatin in combination with continuous infusion 5-fluorouracil (ECF). *Ann Oncol* 1994; 5:609–616.
 5. Wilke M, *et al.* Preliminary analysis of a randomized phase III trial of FAMTX versus ELF versus cisplatin/FU in advanced gastric cancer. A trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group ethe AIO. *Proc Am Soc Clin Oncol* 1995;14:206a.
 6. Shirao K, *et al.* Phase I–II study of irintoecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. *J Clin Oncol* 1997;15:921–927.
 7. MacDonald JS, *et al.* 5-Fluorouracil, Adriamicina, emitomycin (FAM) combination chemotherapy poradvanced gastric cancer. *Ann Intern Med* 1980;93:533–536.
 8. Kelsen D, *et al.* FAMTX versus etoposide, Adriamicina, and cisplatin: a random assignment trial in gastric cancer. *J Clin Oncol* 1992; 10:541–548.
 9. Cullinan SA, *et al.* Controlled evaluation of three drug combination regimens versus fluorouracil alone porthe therapy of advanced gastric cancer. North Central Cancer Treatment Group. *J Clin Oncol* 1994;12:412–416.
 10. Ajani JA, *et al.* Multinational randomized trial of docetaxel, cisplatin with or without 5-fluorouracil in patients with advanced gastric or GE junction adenocarcinoma. *Proc Am Soc Clin Oncol* 2000;20: 165a (abstract 657).
 11. O’Connell MJ. Current status of chemotherapy poradvanced pancreatic egastric cancer. *J Clin Oncol* 1985;3:1032–1039.
 12. Ajani JA. Docetaxel porgastric eesophageal carcinomas. *Oncology* 2002;16 (Suppl 6):89–96.
 13. Hong S *et al.*: A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. *Ann Oncol* 15:1344,2004.

14. Pozzo C *et al*: Irinotecan in combination with Fluorouracil and acid folinic or with cisplatin in patients with advanced gastric cancer , *Ann Oncol* 2004 Dec; 15 (12) : 1773-81.
15. Cao W, Yang W, Lou G, Jiang J, Geng M, Xi W, Li H, Ma T, Jin Y. Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer. *Anticancer Drugs*. 2009 Apr; 20(4): 287-93.
16. Cunningham D, Starling N *et al*. Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. *N Engl J Med* 2008; 358:36-46.
17. Yun J, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. *Eur J Cancer*. 2010 Mar; 46(5):885-91.
18. Schønnemann KR, Jensen HA, Yilmaz M *et al*. Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer. *Br J Cancer*. 2008 Sep 16; 99(6):858-61.
19. Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, Cortesi E *et al*. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. *J Natl Cancer Inst*. 2008 Mar 19; 100(6):388-98. Epub 2008 Mar 11.
20. Thuss-Patience PC, Kretschmar A, Repp M, Kingreen D, Henneser D, Micheel S, Pink D, Scholz C, Dörken B, Reichardt P. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. *J Clin Oncol*. 2005 Jan 20; 23(3):494-501.
21. Ferrari VD, Amoroso V, Valcamonico F *et al*. Epirubicin, cisplatin, and raltitrexed in patients with advanced gastric and hepatobiliary carcinoma: a phase II study. *Am J Clin Oncol*. 2004 Oct; 27(5):445-8.
22. Bang, YJ, Van Cutsem, E, Feyereislova, A, et. al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled Trial. *Lancet*. 2010; 376:687-697.